Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Contineum Therapeutics, Inc. (CTNM) had Non-Operating Income/Expense of $1.96M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-15.16M |
|
-- |
|
-- |
|
$17.11M |
|
$-17.11M |
|
|
Non-Operating Income/Expense |
$1.96M |
$-15.16M |
|
$-15.16M |
|
$-15.16M |
|
$-15.16M |
|
$-15.16M |
|
$-15.16M |
|
$-17.11M |
|
$-17.03M |
|
27.70M |
|
27.70M |
|
$-0.48 |
|
$-0.48 |
|
| Balance Sheet Financials | |
$267.92M |
|
$0.83M |
|
$8.72M |
|
$276.64M |
|
$9.74M |
|
-- |
|
$5.91M |
|
$15.65M |
|
$260.99M |
|
$260.99M |
|
$260.99M |
|
37.32M |
|
| Cash Flow Statement Financials | |
$-55.31M |
|
$-3.71M |
|
$112.69M |
|
$21.94M |
|
$75.60M |
|
$53.66M |
|
$10.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
27.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-55.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.81% |
|
-5.81% |
|
-5.48% |
|
-5.81% |
|
$6.99 |
|
$-2.01 |
|
$-2.00 |
|